Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 6, 2009

Calbiotech Wins Phase I SBIR Contract to Develop Blood-Based Dengue Fever Diagnostic

  • Immunoassay company Calbiotech was awarded a U.S. Army Phase I SBIR grant to develop analyte-specific reagents (ASRs) for diagnosing dengue fever virus in blood or sera. The research will focus on developing and gaining approval for a method of diagnosing dengue fever to facilitate faster medical responses to outbreaks of the infection.

    Dengue virus is a mosquito-borne flavirus that represents a threat to military forces in tropical areas. Calbiotech says that the disease is now endemic in over 100 countries in Africa, the Americas, Eastern Mediterranean, South-East Asia, and the Western Pacific.

    The Phase I award means Calbiotech can also compete for $730,000 in Phase II funding. If achieved, the Phase II project would cover the development of ASRs for the blood or serum-based diagnosis of other diseases including rift valley fever, sand fly fever-Toscana, Crimean-Congo fever, central European tick-borne encephalitis, and chikungunya viruses.

    Calbiotech specializes in the provision of immunoassay products and services. The company offers ELISA, lumELISA™ (ultra-sensitive chemilumenescent ELISA), and radioimmunoassay (RIA) products as well as preclinical testing services.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »